Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Licenses Prenatal Dx Patents from Isis Innovation

NEW YORK, Oct. 20 (GenomeWeb News) - Sequenom today said it has acquired from Isis Innovation exclusive rights in certain countries to non-invasive prenatal diagnostic intellectual property.

 

The IP, which is covered in the United States, United Kingdom, and other countries in Europe, covers non-invasive prenatal genetic testing on fetal nucleic acids derived from plasma or serum. It includes tests for such disorders as cystic fibrosis, hemoglobinopathies, and chromosomal aneuploidies, and enables them to be performed on any platform including mass spectrometry and real time PCR.

 

Financial terms include up-front fees, milestone payments, and royalties on product sales. Isis is the tech-transfer company of the University of Oxford.

"The licensed rights enable the development and performance of tests on any relevant platform, including [Sequenom's flagship] MassArray system," Harry Stylli, Sequenom's president and CEO, said in a statement.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.